Research Article

Integrated Single-Cell RNA-Sequencing Analysis of Gastric Cancer Identifies FABP1 as a Novel Prognostic Biomarker

Table 1

Correlation of the expression of FABP1 in gastric cancer with clinicopathologic features.

CharacteristicsNo. of patientsFABP1 value
Low expression, n (%)High expression, n (%)

Overall9435 (37.2)59 (62.8)
Age0.110
 <60 years, n (%)25 (26.6)19 (76.0)6 (24.0)
 ≥60 years, n (%)69 (73.4)40 (58.0)29 (42.0)
Gender0.385
 Female59 (62.8)39 (66.1)20 (33.9)
 Male35 (37.2)20 (57.1)15 (42.9)
Tumor size0.565
 <5.0 cm33 (35.1)22 (66.7)11 (33.3)
 ≥5.0 cm61 (64.9)37 (60.7)24 (39.3)
Primary tumor location0.770
 Gastric cardial + body60 (63.8)37 (61.7)23 (38.3)
 Gastric antral34 (36.2)22 (64.7)12 (35.3)
Pathological type0.534
 Adenocarcinoma78 (83.0)50 (64.1)28 (35.9)
 Mucinous + signet-ring cell carcinoma16 (17.0)9 (56.3)7 (43.7)
Lymph node metastasis0.684
 Negative72 (76.6)46 (63.9)26 (36)
 Positive22 (23.4)13 (59.1)9 (40.9)
TNM stage0.370
 I + II35 (37.2)24 (68.6)11 (31.4)
 III + IV59 (62.8)35 (59.3)24 (40.7)
HER20.668
 Positive6 (6.4)5 (83.3)1 (16.7)
 Negative88 (93.6)54 (61.4)34 (38.6)